Analysis of mutations in the FGFR3 gene, using the urine based CertNDxTM Bladder Cancer Assay, detected cancer indicating that the tumor was malignant; which was subsequently confirmed by pathology. This evidence concerns the gene FGFR3 and neoplasm.